BioSpace News Archive

LeMaitre Vascular, Inc. announced that management will be participating in four upcoming investor conferences in March.

Iovance Biotherapeutics, Inc., a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte therapies for patients with cancer, announced that senior leadership plans to present at the following conferences.

Kura Oncology, Inc. announced that on March 1, 2024, the Compensation Committee of the Company’s Board of Directors granted inducement awards consisting of nonstatutory stock options to purchase 93,000 shares of common stock to two new employees under the Company’s 2023 Inducement Option Plan.

LENSAR, Inc. announced that a majority of the independent members of LENSAR’s board of directors granted seven newly-hired non-executive employees stock options to purchase an aggregate of 4,175 shares of the Company’s common stock.

Taysha Gene Therapies, Inc. announced that, on March 1, 2024, the Compensation Committee of Taysha’s Board of Directors granted four new employees, in the aggregate, options to purchase 347,000 shares of the Company’s common stock in connection with their employment.

Mezzion Pharmaceuticals is a rare disease company conducting the confirmatory pivotal phase 3 clinical trial in Fontan subjects: The Fontan Udenafil Exercise Longitudinal Assessment Trial- 2, or FUEL-2 trial.

Spyre Therapeutics, Inc. announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grants of stock options to purchase an aggregate of 166,200 shares of common stock of Spyre to four non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended.

MacroGenics, Inc., a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced that the Company’s management will participate in the following investor conferences in March 2024.

Zentalis® Pharmaceuticals, Inc. announced that on March 1, 2024, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 125,000 shares of the Company’s common stock to two newly hired employees.

Adial Pharmaceuticals, Inc. announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,150,000 shares of common stock of the Company originally issued in October 2023, having an exercise price of $2.82 per share and eighteen months term.